A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs AMG 820 (Primary) ; Pembrolizumab
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Apr 2019.
- 08 Mar 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2019.